# **Greater combined reductions of HbA**<sub>1c</sub> ≥1.0% and body weight loss ≥5.0% or ≥10.0% with oral semaglutide versus comparators

Kathleen M. Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C. Woo, Tina Vilsbøll

### What is the background?

For patients with type 2 diabetes, two important goals of treatment are bringing blood sugar levels under control and body weight loss1






### Why is this study needed?

Combined study outcomes provide a holistic view to help doctors decide what medicine to give to patients with type 2 diabetes<sup>2</sup>

## What was investigated?

This study looked at the extent at which patients with type 2 diabetes treated with oral semaglutide achieved both lower blood sugar levels and body weight loss versus comparators **Outcomes** 



### What were the results?

Oral semaglutide was **better than** placebo and comparators in **reducing** blood sugar levels by more than or equal to 1% and body weight loss more than or egual to 5% at week 26 and at the end of treatment



Oral semaglutide was also better than placebo and comparators when the larger body weight loss target of more than or equal to 10% was used

#### What does this mean?



 More patients who received treatment with oral semaglutide had improved blood sugar control and experienced greater body weight loss compared with patients who received placebo or comparators



Combined outcomes of reduced blood sugar levels and body weight loss may help doctors suggest suitable treatment options for patients with type 2 diabetes

References: 1. Rodbard HW, et al. Endocr Pract. 2019;25:589-597; 2. Aroda VR, et al. Diabetes Care. 2019;42:1724-1732; 3. Unnikrishnan AG, et al. Indian J Endocrinol Metab. 2013;17:835-843; 4. Rodbard HW, et al. Diabetes Care. 2019;42:2272-2281; 5. Rosenstock J, et al. JAMA. 2019;321:1466-1480; 6. Pratley R, et al. Lancet. 2019;394:39-50; 7. Mosenzon O, et al. Lancet Diabetes Endocrinol. 2019;7:515-527; 8. Zinman B, et al. Diabetes Care. 2019;42:2262-2271. This plain language summary infographic represents the opinions of the authors. For a full list of

declarations, including funding and author disclosure statements, and copyright information, please see the full text online.



